DOCSLIB.ORG

Prior Authorization Medications Requiring

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Prior Authorization Medications Requiring Prior Authorization Medications Requiring Review – Criteria for Use The Medicare Part D formulary does not allow prior authorization or criteria restrictions on medications; this document applies to the Commercial, Triple Tier, Multi-Choice, and Qualified Health Plans formularies. * The Pharmacy Consult Service reviews criteria restrictions for Diabetes, Hepatitis C, Multiple Sclerosis Medications, and PCSK9 Inhibitors Brand Name and/or Generic Name J-Code Medicare Status Notes Therapeutic Class Acthar® Corticotropin gel J0800 Medicare Part D Reviewed by the Pharmacy Consult Service for Mutiple Sclerosis indication only Aimovig™ Erenumab-aooe Medicare Part D Ampyra™ Dalfampridine Medicare Part D Reviewed by the Pharmacy Consult Service Arcalyst™ Rilonacept powder for solution J3490 Medicare Part D Aubagio® Teriflunomide Medicare Part D Reviewed by the Pharmacy Consult Service Berinert® Human C1 Inhibitor Medicare Part D Botulinum Toxin: Medicare Part D Botox® (P) Botulinum Toxins Type A J0585 (type Dysport™ (N) Botulinum Toxins Type B A) Myobloc® (N) J0587 (type Xeomin® (N) B) Cerdelga™ Eliglustat Medicare Part D Cholbam® cholic acid Medicare Part D Last Revised: August 22, 2018 CONFIDENTIAL: FOR INTERNAL KAISER PERMANENTE USE ONLY Page 1 of 91 Brand Name and/or Generic Name J-Code Medicare Status Notes Therapeutic Class Cinqair® Reslizumab Medicare Part B or D Daklinza® Daclatasvir Medicare Part D Reviewed by the Pharmacy Consult Service Dipeptidyl peptidase 4 (DPP- Medicare Part D Reviewed by the IV) inhibitors*: Pharmacy Januvia™ Sitagliptin Consult Service Sitagliptin and metformin Janumet™ Linagliptin and metformin Jentadueto® XR Alogliptin Nesina™ Saxagliptin Onglyza™ Alogliptin and metformin Kazano™ Saxagliptin and metformin ER Kombiglyze™ XR Alogliptin and pioglitazone Oseni™ Linagliptin and empagliflozin Glyxambi™ Saxagliptin and dapagliflozin Qtern® Sitagliptin and ertugliflozin Steglujan™ Last Revised: August 22, 2018 CONFIDENTIAL: FOR INTERNAL KAISER PERMANENTE USE ONLY Page 2 of 91 Brand Name and/or Generic Name J-Code Medicare Status Notes Therapeutic Class Dupixent® Dupilumab Medicare Part D Eloctate® Antihemophilic Factor Medicare Part B (Recombinant) Emflaza® Deflazacort Medicare Part D Entyvio® Vedolizumab Medicare Part B or D Enzyme replacement therapy: Velaglucerase Alfa Vpriv® (P) Imiglucerase Cerezyme® (N) Taliglucerase Alfa Elelyso® (N) Epclusa® sofosbuvir and velpatasvir Medicare Part D Reviewed by the Pharmacy Consult Service Exondys 51™ Eteplirsen Fabrazyme Agalsidase Beta Fasenra Benralizumab Medicare Part B or D Firazyr® (N) Icatibant Medicare Part D Gattex® (N) Teduglutide Medicare Part D Gilenya™ (N) Fingolimod Medicare Part D Reviewed by the Pharmacy Consult Service Glatiramer acetate Medicare Part D Reviewed by the Copaxone® Glatiramer acetate Pharmacy Glatiramer acetate Consult Service GLP-1 Receptor Agonists*: Medicare Part D Reviewed by the Bydureon™ (P) Exenatide Extended-Release Pharmacy Consult Victoza® (N) Liraglutide injection Service Byetta™ (N) Exenatide SQ solution Trulicity (N) Dulaglutide Adlyxin (N) Lixisenatide Soliqua (N) Insulin glargine/lixesenatide Xultophy (N) Insulin degludec/liraglutide Ozempic (N) Semaglutide Growth Hormones: Somatropin (Growth hormone) J2940-J2941 Medicare Part D Omnitrope® (P) injectable Genotropin® (N) Humatrope® (N) Norditropin® (N) Nutropin AQ (N) Saizen® (N) Last Revised: August 22, 2018 CONFIDENTIAL: FOR INTERNAL KAISER PERMANENTE USE ONLY Page 3 of 91 Brand Name and/or Generic Name J-Code Medicare Status Notes Therapeutic Class Serostim® (N) Zorbtive® (N) Harvoni® Ledipasvir and sofosbuvir Medicare Part D Reviewed by the Pharmacy Consult Service Hemlibra Emicizumab-kxwh Medicare Part D Human C1 Esterase Human C1 Esterase Inhibitor Medicare Part B or Inhibitors: D Cinryze® Haegarda® Hetlioz® Tasimelteon Medicare Part D Hyaluronic Acid Derivatives Hyaluronic Acid Injections J7321-J7322 Medicare Part B (viscosupplements): Supartz® (P) Synvisc® (2) Euflexxa® (N) Hyalgan® (N) Orthovisc® (N) Synvisc-One® (N) Hyzentra Immune globulin (subcutaneous) Medicare Part B Hyqvia Immune globulin and recombinant Medicare Part D or human hyaluronidase B Ilaris® Canakinumab Medicare Part D Ingrezza® Valbenazine Medicare Part D Interleukin (IL) Antagonists: Stelara® (P) Ustekinumab Taltz® Ixekizumab Medicare Part D Tremfya Guselkumab Siliq™ Brodalumab Impavido® Miltefosine Medicare Part D Interferons: Reviewed by the Avonex® (P) Interferon beta-1a Pharmacy Medicare Part D Rebif® (P) Interferon beta-1a Consult Service Plegridy® (N) Peginterferon beta-1a Last Revised: August 22, 2018 CONFIDENTIAL: FOR INTERNAL KAISER PERMANENTE USE ONLY Page 4 of 91 Brand Name and/or Generic Name J-Code Medicare Status Notes Therapeutic Class Jetrea® Ocriplasmin Juxtapid™ Lomitapide Medicare Part D Kalbitor® Ecallantide Medicare Part D Kalydeco™ Ivacaftor Medicare Part D Keveyis® Dichlorphenamide Medicare Part D Korlym™ Mifepristone Medicare Part D Kuvan™ Sapropterin tablets J3490 Medicare Part D Kynamro™ Mipomersen sodium Medicare Part D Lemtrada® Alemtuzumab Medicare Part B Reviewed by the Pharmacy Consult Service MavyretTM Glaceprevir and Pibrentasvir Medicare Part D Reviewed by the Pharmacy Consult Service Natpara® Parathyroid hormone Medicare Part D Nucala® Mepolizumab Medicare Part B or D Ocrevus™ Ocrelizumab Medicare Part B Reviewed by the Pharmacy Consult Service Olysio® Simeprevir Medicare Part D Reviewed by the Pharmacy Consult Service Orkambi® lumacaftor and ivacaftor Medicare Part D Parathyroid Hormone Medicare Part D Analogs: Forteo® (P) Teriparatide Tymlos® Abaloparatide PCSK-9 Inhibitors: Medicare Part D Reviewed by the Repatha® Evolocumab Pharmacy Praluent® Alirocumab Consult Service Procysbi™ Cysteamine delayed-release Medicare Part D Prolia® Denosumab Medicare Part B or D Provenge® Sipuleucel-T Q2043 Medicare Part B Radicava® Endavarone Medicare Part B or D Ravicti® Glycerol phenylbutyrate Medicare Part D Ruconest® C1 inhibitor (recombinant) Medicare Part B or D Sabril® Vigabatrin Medicare Part D Last Revised: August 22, 2018 CONFIDENTIAL: FOR INTERNAL KAISER PERMANENTE USE ONLY Page 5 of 91 Brand Name and/or Generic Name J-Code Medicare Status Notes Therapeutic Class Sodium-Glucose Medicare Part D Reviewed by the Cotransporter 2 (SGLT2) Pharmacy Consult Inhibitors*: Service Synjardy™ Empagliflozin and metformin Invokana™ Canagliflozin Farxiga™ Dapagliflozin Steglatro™ Ertugliflozin Glyxambi™ Empagliflozin and linagliptin Invokamet™ Canagliflozin and metformin Invokamet XR Canagliflozin and metformin Xigduo XR™ Dapagliflozin and metformin Segluromet™ Ertugliflozin and metformin Somavert® Pegvisomant Medicare Part D Sovaldi® Sofosbuvir Medicare Part D Reviewed by the Pharmacy Consult Service Spinraza™ Nusinersen Supprelin® LA Histrelin implant J9226 Medicare Part D Symdeko Tezafactor/Ivacaftor Medicare Part D Symlin*® Pramlintide SQ solution J3490 Medicare Part D Reviewed by the Pharmacy Consult Service Tecfidera™ Dimethyl fumarate Medicare Part D Reviewed by the Pharmacy Consult Service Technivie® Ombitasvir/paritaprevir/ ritonavir Medicare Part D Reviewed by the Pharmacy Consult Service Last Revised: August 22, 2018 CONFIDENTIAL: FOR INTERNAL KAISER PERMANENTE USE ONLY Page 6 of 91 Brand Name and/or Generic Name J-Code Medicare Status Notes Therapeutic Class Tysabri® Natalizumab IV solution J2323 Medicare Part B Reviewed by the Pharmacy Consult Service for Mutiple Sclerosis indication only Viberzi® Eluxadoline Medicare Part D Viekira Pak® Ombitasvir, Paritaprevir, Ritonavir, Medicare Part D Reviewed by the Viekira XR® and Dasabuvir Pharmacy Consult Service VMAT2 Inhibitors: Medicare Part D Austedo® Deutetrabenazine Xenazine® Tetrabenazine Vosevi® Sofosbuvir/velpatasvir/voxilaprevir Medicare Part D Reviewed by the Pharmacy Consult Service Xgeva® Denosumab Medicare Part B Xiaflex™ Collagenase clostridium J0775 Medicare Part B histolyticum injection Xolair® Omalizumab injectable J2357 Medicare Part D Zavesca® Miglustat Zepatier® Elbasvir and Grazoprevir Medicare Part D Reviewed by the Pharmacy Consult Service P- Preferred when criteria met 2-2nd line (if preferred failed) NP- Non-preferred Last Revised: August 22, 2018 CONFIDENTIAL: FOR INTERNAL KAISER PERMANENTE USE ONLY Page 7 of 91 Medications Requiring Review – Criteria for Use Drug Prior Authorization Criteria Acthar® Candidates for treatment with Acthar® should meet the following pertinent criteria: (Corticotropin (gel)) Acthar® gel will not be covered in patients with any of the following diagnoses: • Congestive heart failure • Uncontrolled Hypertension • Osteoporosis • History of or presence of peptic ulcer • Primary adrenocortical insufficiency or adrenocortical hyperactivity • Scleroderma • Hypersensitivity to porcine protein • Pancreatitis • Thromboembolic disorder • Ocular herpes simplex • Systemic fungal infections Criteria for use for diagnosis of infantile spasms: 1. Diagnosis of infantile spasms 2. Less than 2 years of age 3. Prescribed by pediatric neurologist or neurologist Criteria for use for Nephritic Syndrome: 1. A diagnosis of idiopathic nephritic syndrome 2. Prescriber must be a nephrologist 3. Patient failed to achieve a sustained partial or complete remission of nephritic syndrome after 6 months of therapy with first line therapy (i.e., corticosteroids) AND after 6 months of therapy with second line therapies with demonstrated efficacy (i.e., cyclosporine, tacrolimus, rituximab, and mycophenolate mofetil). Patient is expected to continue therapy for at least 3 months and is able to afford
Load more

Recommended publications
  • 2020 Prior Authorization Criteria
    2020 PRIOR AUTHORIZATION CRITERIA TABLE OF CONTENTS abiraterone tablet ...................................................................................................................... 217 ABRAXANE .............................................................................................................................. 131 ACTIMMUNE .............................................................................................................................. 14 ADASUVE ................................................................................................................................... 27 ADEMPAS ................................................................................................................................ 197 AFINITOR ................................................................................................................................. 217 AFINITOR DISPERZ ................................................................................................................. 217 AIMOVIG ..................................................................................................................................... 15 ALECENSA ............................................................................................................................... 217 ALIMTA ..................................................................................................................................... 131 ALIQOPA .................................................................................................................................
    [Show full text]
  • Review of Current Real-World Experience with Teriparatide As Treatment of Osteoporosis in Different Patient Groups
    Journal of Clinical Medicine Review Review of Current Real-World Experience with Teriparatide as Treatment of Osteoporosis in Different Patient Groups Barbara Hauser 1,2,* , Nerea Alonso 2 and Philip L Riches 1,2 1 Rheumatic Disease Unit, Western General Hospital, NHS Lothian, Edinburgh EH4 2XU, UK; [email protected] 2 Rheumatology and Bone Disease Unit, Centre for Genomic and Experimental Medicine, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XU, UK; [email protected] * Correspondence: [email protected] Abstract: Teriparatide has proven effective in reducing both vertebral and non-vertebral fractures in clinical trials of post-menopausal and glucocorticoid-induced osteoporosis. Widespread adoption of Teriparatide over the last two decades means that there is now substantial experience of its use in routine clinical practice, which is summarized in this paper. Extensive real-world experience of Teriparatide in post-menopausal osteoporosis confirms the fracture and bone density benefits seen in clinical trials, with similar outcomes identified also in male and glucocorticoid-induced osteoporosis. Conversely, very limited experience has been reported in pre-menopausal osteoporosis or in the use of Teriparatide in combination with other therapies. Surveillance studies have identified no safety signals relating to the possible association of Teriparatide with osteosarcoma. We also review the evidence for predicting response to Teriparatide in order to inform the debate on where best to use Teriparatide in an increasingly crowded therapeutic landscape. Citation: Hauser, B.; Alonso, N.; Riches, P.L. Review of Current Keywords: Teriparatide; anabolic treatment; osteoporosis; fracture Real-World Experience with Teriparatide as Treatment of Osteoporosis in Different Patient Groups.
    [Show full text]
  • The Activation of the Glucagon-Like Peptide-1 (GLP-1) Receptor by Peptide and Non-Peptide Ligands
    The Activation of the Glucagon-Like Peptide-1 (GLP-1) Receptor by Peptide and Non-Peptide Ligands Clare Louise Wishart Submitted in accordance with the requirements for the degree of Doctor of Philosophy of Science University of Leeds School of Biomedical Sciences Faculty of Biological Sciences September 2013 I Intellectual Property and Publication Statements The candidate confirms that the work submitted is her own and that appropriate credit has been given where reference has been made to the work of others. This copy has been supplied on the understanding that it is copyright material and that no quotation from the thesis may be published without proper acknowledgement. The right of Clare Louise Wishart to be identified as Author of this work has been asserted by her in accordance with the Copyright, Designs and Patents Act 1988. © 2013 The University of Leeds and Clare Louise Wishart. II Acknowledgments Firstly I would like to offer my sincerest thanks and gratitude to my supervisor, Dr. Dan Donnelly, who has been nothing but encouraging and engaging from day one. I have thoroughly enjoyed every moment of working alongside him and learning from his guidance and wisdom. My thanks go to my academic assessor Professor Paul Milner whom I have known for several years, and during my time at the University of Leeds he has offered me invaluable advice and inspiration. Additionally I would like to thank my academic project advisor Dr. Michael Harrison for his friendship, help and advice. I would like to thank Dr. Rosalind Mann and Dr. Elsayed Nasr for welcoming me into the lab as a new PhD student and sharing their experimental techniques with me, these techniques have helped me no end in my time as a research student.
    [Show full text]
  • DRUGS REQUIRING PRIOR AUTHORIZATION in the MEDICAL BENEFIT Page 1
    Effective Date: 08/01/2021 DRUGS REQUIRING PRIOR AUTHORIZATION IN THE MEDICAL BENEFIT Page 1 Therapeutic Category Drug Class Trade Name Generic Name HCPCS Procedure Code HCPCS Procedure Code Description Anti-infectives Antiretrovirals, HIV CABENUVA cabotegravir-rilpivirine C9077 Injection, cabotegravir and rilpivirine, 2mg/3mg Antithrombotic Agents von Willebrand Factor-Directed Antibody CABLIVI caplacizumab-yhdp C9047 Injection, caplacizumab-yhdp, 1 mg Cardiology Antilipemic EVKEEZA evinacumab-dgnb C9079 Injection, evinacumab-dgnb, 5 mg Cardiology Hemostatic Agent BERINERT c1 esterase J0597 Injection, C1 esterase inhibitor (human), Berinert, 10 units Cardiology Hemostatic Agent CINRYZE c1 esterase J0598 Injection, C1 esterase inhibitor (human), Cinryze, 10 units Cardiology Hemostatic Agent FIRAZYR icatibant J1744 Injection, icatibant, 1 mg Cardiology Hemostatic Agent HAEGARDA c1 esterase J0599 Injection, C1 esterase inhibitor (human), (Haegarda), 10 units Cardiology Hemostatic Agent ICATIBANT (generic) icatibant J1744 Injection, icatibant, 1 mg Cardiology Hemostatic Agent KALBITOR ecallantide J1290 Injection, ecallantide, 1 mg Cardiology Hemostatic Agent RUCONEST c1 esterase J0596 Injection, C1 esterase inhibitor (recombinant), Ruconest, 10 units Injection, lanadelumab-flyo, 1 mg (code may be used for Medicare when drug administered under Cardiology Hemostatic Agent TAKHZYRO lanadelumab-flyo J0593 direct supervision of a physician, not for use when drug is self-administered) Cardiology Pulmonary Arterial Hypertension EPOPROSTENOL (generic)
    [Show full text]
  • Bradykinin B2 Receptor Modulates Renal Prostaglandin E2 and Nitric Oxide
    (Hypertension. 1997;29:757-762.) © 1997 American Heart Association, Inc. Bradykinin B2 Receptor Modulates Renal Prostaglandin E2 and Nitric Oxide Helmy M. Siragy; Ayad A. Jaffa; Harry S. Margolius the Department of Internal Medicine, University of Virginia Health Sciences Center, Charlottesville, and the Departments of Pharmacology and Medicine, Medical University of South Carolina and Ralph A. Johnson VA Medical Center, Charleston. Correspondence to Helmy M. Siragy, MD, Department of Medicine, Box 482, University of Virginia Health Sciences Center, Charlottesville, VA 22908. ABSTRACT Bradykinin and lys-bradykinin generated intrarenally appear to be important renal paracrine hormones. However, the renal effects of endogenously generated bradykinin are still not clearly defined. In this study, we measured acute changes in renal excretory and hemodynamic functions and renal cortical interstitial fluid levels of bradykinin, prostaglandin E2, and cGMP in response to an acute intrarenal arterial infusion of the bradykinin B2 receptor antagonist Hoe 140 (icatibant), cyclooxygenase inhibitor indomethacin, or nitric oxide synthase inhibitor NG-monomethyl-L-arginine (L-NMMA) given individually or combined in uninephrectomized, conscious dogs (n=10) in low sodium balance. Icatibant caused a significant decrease in urine flow, urinary sodium excretion, and renal plasma flow rate (each P<.001). Glomerular filtration rate did not change during icatibant administration. Icatibant produced an unexpected large increase in renal interstitial fluid bradykinin (P<.0001) while decreasing renal interstitial fluid prostaglandin E2 and cGMP (each P<.001). Both indomethacin and L-NMMA when given individually caused significant antidiuresis and antinatriuresis and decreased renal blood flow (each P<.001). Glomerular filtration rate decreased during L-NMMA administration (P<.001) and did not change during indomethacin administration.
    [Show full text]
  • Novel Therapies in Osteoporosis: PTH-Related Peptide Analogs and Inhibitors of Sclerostin
    62 2 Journal of Molecular T D Rachner et al. Novel anabolic osteoporosis 62:2 R145–R154 Endocrinology treatments REVIEW Novel therapies in osteoporosis: PTH-related peptide analogs and inhibitors of sclerostin Tilman D Rachner1,2,3, Lorenz C Hofbauer1,2,3,4, Andy Göbel1,3 and Elena Tsourdi1,2,3 1Department of Medicine III, Technische Universität Dresden Medical Center, Dresden, Germany 2Center for Healthy Aging, Technische Universität Dresden Medical Center, Dresden, Germany 3German Cancer Consortium (DKTK), partner site Dresden and German Cancer Research Center (DKFZ), Dresden, Germany 4Center for Regenerative Therapies Dresden, Technische Universität Dresden, Dresden, Germany Correspondence should be addressed to T D Rachner: [email protected] Abstract Bone-forming approaches to treat patients with severe osteoporosis are effective, but Key Words treatment options are limited, and there is an unmet clinical need for additional drugs. f PTH This review discusses two novel and advanced anabolic therapeutic concepts that f PTH-related protein have successfully completed phase 3 trials. Romosozumab is a monoclonal antibody f abaloparatide that targets the Wnt inhibitor sclerostin. Two phase 3 trials (FRAME and ARCH) of f sclerostin romosozumab for the treatment of postmenopausal osteoporosis have been completed. f sclerostin antibody Both trials successfully reached their primary endpoint by reducing vertebral fractures by f romosozumab 75% compared to placebo (FRAME trial) and 48% compared to alendronate (ARCH trial), respectively. Abaloparatide is a PTH-related protein (PTHrP) analog that has displayed bone anabolic activity. In the phase 3 ACTIVE trial, abaloparatide was compared to placebo and teriparatide for 18 months in postmenopausal women who had already experienced an osteoporotic fracture.
    [Show full text]
  • NMR Spectroscopy for Protein Higher Order Structure Similarity Assessment in Formulated Drug Products
    molecules Article NMR Spectroscopy for Protein Higher Order Structure Similarity Assessment in Formulated Drug Products Deyun Wang 1, You Zhuo 2, Mike Karfunkle 3, Sharadrao M. Patil 2, Cameron J. Smith 4, David A. Keire 5 and Kang Chen 2,* 1 Northeast Medical Products Laboratory, Office of Regulatory Science, Office of Regulatory Affairs, U.S. Food and Drug Administration, Jamaica, NY 11433, USA; [email protected] 2 Division of Complex Drug Analysis, Office of Testing and Research, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA; [email protected] (Y.Z.); [email protected] (S.M.P.) 3 Division of Pharmaceutical Analysis, Office of Testing and Research, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, St. Louis, MO 63110, USA; [email protected] 4 Division of Liquid Based Products I, Office of Lifecycle Drug Products, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA; [email protected] 5 Office of Testing and Research, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, St. Louis, MO 63110, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-240-402-5550 Abstract: Peptide and protein drug molecules fold into higher order structures (HOS) in formulation and these folded structures are often critical for drug efficacy and safety. Generic or biosimilar drug Citation: Wang, D.; Zhuo, Y.; products (DPs) need to show similar HOS to the reference product.
    [Show full text]
  • AACE Annual Meeting 2021 Abstracts Editorial Board
    June 2021 Volume 27, Number 6S AACE Annual Meeting 2021 Abstracts Editorial board Editor-in-Chief Pauline M. Camacho, MD, FACE Suleiman Mustafa-Kutana, BSC, MB, CHB, MSC Maywood, Illinois, United States Boston, Massachusetts, United States Vin Tangpricha, MD, PhD, FACE Atlanta, Georgia, United States Andrea Coviello, MD, MSE, MMCi Karel Pacak, MD, PhD, DSc Durham, North Carolina, United States Bethesda, Maryland, United States Associate Editors Natalie E. Cusano, MD, MS Amanda Powell, MD Maria Papaleontiou, MD New York, New York, United States Boston, Massachusetts, United States Ann Arbor, Michigan, United States Tobias Else, MD Gregory Randolph, MD Melissa Putman, MD Ann Arbor, Michigan, United States Boston, Massachusetts, United States Boston, Massachusetts, United States Vahab Fatourechi, MD Daniel J. Rubin, MD, MSc Harold Rosen, MD Rochester, Minnesota, United States Philadelphia, Pennsylvania, United States Boston, Massachusetts, United States Ruth Freeman, MD Joshua D. Safer, MD Nicholas Tritos, MD, DS, FACP, FACE New York, New York, United States New York, New York, United States Boston, Massachusetts, United States Rajesh K. Garg, MD Pankaj Shah, MD Boston, Massachusetts, United States Staff Rochester, Minnesota, United States Eliza B. Geer, MD Joseph L. Shaker, MD Paul A. Markowski New York, New York, United States Milwaukee, Wisconsin, United States CEO Roma Gianchandani, MD Lance Sloan, MD, MS Elizabeth Lepkowski Ann Arbor, Michigan, United States Lufkin, Texas, United States Chief Learning Officer Martin M. Grajower, MD, FACP, FACE Takara L. Stanley, MD Lori Clawges The Bronx, New York, United States Boston, Massachusetts, United States Senior Managing Editor Allen S. Ho, MD Devin Steenkamp, MD Corrie Williams Los Angeles, California, United States Boston, Massachusetts, United States Peer Review Manager Michael F.
    [Show full text]
  • Role of the Intracellular Domains in the Regulation and the Signaling of the Human Bradykinin B2 Receptor
    Aus der Abteilung für Klinische Chemie und Klinische Biochemie in der Chirurgischen Klinik-Innenstadt der Ludwig-Maximilians-Universität München Leiterin der Abteilung: Prof. Dr. rer. nat. Dr. med. habil. Marianne Jochum Role of the intracellular domains in the regulation and the signaling of the human bradykinin B2 receptor Dissertation zum Erwerb des Doktorgrades der Humanbiologie an der Medizinischen Fakultät der Ludwig-Maximilians-Universität zu München Vorgelegt von Göran Wennerberg aus Stockholm 2010 Mit Genehmigung der Medizinischen Fakultät der Ludwig-Maximilians-Universität München Berichterstatter: PD Dr. rer. nat. Alexander Faussner Mitberichterstatter: Prof. Dr. Nikolaus Plesnila Prof. Dr. Franz-Xaver Beck Mitbetreuung durch den promovierten Mitarbeiter: Dekan: Prof. Dr. med. Dr. h.c. M. Reiser, FACR,FRCR Tag der mündlichen Prüfung: 27.01.2010 CONTENTS………………………………………………………………………………………I ABBREVIATIONS………………………………………………………………………………V A ZUSAMMENFASSUNG ............................................................................................ 1 B INTRODUCTION ....................................................................................................... 4 B.1 The kallikrein-kinin system (KKS) B.1.1 Historic background............................................................................................................................................4 B.1.2 Kinins...................................................................................................................................................................4
    [Show full text]
  • 2017 Fda Peptide Harvest
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 10 April 2018 doi:10.20944/preprints201804.0126.v1 Peer-reviewed version available at Pharmaceuticals 2018, 11, 42; doi:10.3390/ph11020042 1 Review 2 2017 FDA PEPTIDE HARVEST 3 Othman Al Musaimi,1,2,# Danah Alshaer, 1,2,# Beatriz G. de la Torre,3,* Fernando Albericio,2,4,5.* 4 1 College of Health Sciences, University of KwaZulu-Natal, Durban 4000, South Africa 5 2 School of Chemistry, University of KwaZulu-Natal, Durban 4001, South Africa 6 3 KRISP, College of Health Sciences, University of KwaZulu-Natal, Durban 4001, South Africa 7 4 CIBER-BBN, Networking Centre on Bioengineering, Biomaterials and Nanomedicine, University of 8 Barcelona, 08028 Barcelona, Spain 9 5 Department of Organic Chemistry, University of Barcelona, 08028 Barcelona, Spain 10 * Correspondence: [email protected]; [email protected]; Tel.: +27-614009144 11 12 13 Abstract: 2017 was an excellent year in terms of new drugs (chemical entities and biologics) 14 approved by the FDA, with a total of forty-six. In turn, one of the highlights was the number of 15 peptides (six) included in this list. Here, the six peptides are analysed in terms of chemical structure, 16 synthetic strategy used for their production, source, biological target, and mode of action. 17 Keywords: pharmaceutical market; drugs; drug discovery; solid-phase peptide synthesis 18 Introduction 19 The financial investment associated with the pharmaceutical industry is one of the largest in the 20 industrial sector—surpassed only by the telecommunications sector. However, the number of new 21 products (drugs) entering the market each year is relatively low.
    [Show full text]
  • Icatibant (Firazyr) Reference Number: CP.PHAR.178 Effective Date: 03/16 Coding Implications Last Review Date: 03/17 Revision Log
    Clinical Policy: Icatibant (Firazyr) Reference Number: CP.PHAR.178 Effective Date: 03/16 Coding Implications Last Review Date: 03/17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description The intent of the criteria is to ensure that patients follow selection elements established by Centene® clinical policy for icatibant (Firazyr®). Policy/Criteria It is the policy of health plans affiliated with Centene Corporation® that Firazyr is medically necessary when one of the following criteria is met: I. Initial Approval Criteria A. Hereditary Angioedema (HAE) (must meet all): 1. Diagnosis of HAE confirmed by one of the following (a or b): a. Low C4 level and low C1-INH antigenic or functional level (see Appendix B); b. Normal C4 level and normal C1-INH levels, and all of the following (i - iii): i. History of recurrent angioedema; ii. Family history of angioedema; iii. Other types of angioedema have been ruled out (e.g., ACE-I/ARB-associated or other drug-induced angioedema, allergic angioedema, nonhistaminergic angioedema); 2. Prescribed for treatment of acute attacks; 3. Prescribed dose of Firazyr does not exceed 30 mg per dose (1 syringe per dose) with up to 3 doses administered in a 24 hour period. Approval duration: 12 months (no more than 6 doses per month) B. Other diagnoses/indications: Refer to CP.PHAR.57 - Global Biopharm Policy. II. Continued Approval A. Hereditary Angioedema (must meet all): 1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria; 2. Documentation of positive response to therapy; 3.
    [Show full text]
  • The European Pharmacopoeia (Ph. Eur.)
    THE EUROPEAN DIRECTORATE FOR THE QUALITY OF MEDICINES & HEALTHCARE (EDQM) European Directorate for the Quality of Medicines & HealthCare • A Council of Europe Directorate, based on the Convention on the Elaboration of a European Pharmacopoeia (PA, 1964) • Mission: to contribute to a basic human right: access to good quality medicines and healthcare • See www.edqm.eu for further information 2 ©2020 EDQM, Council of Europe. All rights reserved. Key players for the quality of medicines in Europe National Authorities EU Coordination of scientific DG Health and resources from MS Food Safety Licensing Authorities Inspectorates Control Laboratories Pharmacopoeia Authorities Pharmaceutical legislation National Authorities EU & non-EU European Pharmacopoeia OMCL, Certification, Healthcare…. 3 ©2020 EDQM, Council of Europe. All rights reserved. •EDQM Laboratory •Established in 1967 •Located in Strasbourg, France • - Analytical Chemistry Division • - Biological Section 4 ©2020 EDQM, Council of Europe. All rights reserved. Role of the EDQM Laboratory European • establish/monitor Ph. Eur. reference substances (CRS) Pharmacopoeia • support elaboration of Ph. Eur. monographs / chapters (Ph. Eur.) • support the biological standardisation programme European • support the annual PTS programme OMCL network WHO • establish/monitor ICRS (Ref. Standards for the Ph. Int.) • establish/monitor ISA (Int’l Standards for Antibiotics) • participate in int’l studies on RS 5 ©2020 EDQM, Council of Europe. All rights reserved. European Pharmacopoeia Reference Standards for Biologicals Frank Jung, Ph.D. EDQM Laboratory Department Biological Section 6 ©2020 EDQM, Council of Europe. All rights reserved. The European Pharmacopoeia (Ph. Eur.) A compendium of quality standards for substances for pharmaceutical use and medicinal products Legally binding in 39 countries signatories of the Ph.
    [Show full text]